Zevra Therapeutics, Inc. (ZVRA)
(Real Time Quote from BATS)
$4.64 USD
+0.05 (0.98%)
Updated May 30, 2024 10:20 AM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ZVRA 4.64 +0.05(0.98%)
Will ZVRA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
Other News for ZVRA
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
Strong Buy Rating for Zevra Therapeutics Based on Solid Financials and Promising Drug Pipeline
Zevra Therapeutics to Participate at Upcoming Investor Events
Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...